Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
120.50    0.00 (0.00%)
Bid:
118.00
Ask:
123.00
Spread: 5.00 (4.237%)
Market Cap: £72.50m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

5 Apr 2017 07:00

RNS Number : 5897B
Intercede Group PLC
05 April 2017
 

 

5 April 2017

INTERCEDE GROUP plc

("Intercede", or the "Group")

Trading Update

 

Intercede announced on 3 March 2017 that the revenue outturn for the financial year ending 31 March 2017 would be approximately £8.0m, with a further £2.0m of new orders in the near term pipeline. The Group today confirms that three of these contract orders were received by the end of the trading period. Subject to the completion of the year end audit, revenues for the year ending 31 March 2017 are expected to be between £8.2 - 8.4m.

The new orders include two customer wins that relate to the deployment of MyID within a US Government Agency and a US Healthcare group. Intercede continues to work diligently to bring the remainder of the near term pipeline into reported revenue. It is confident that this will occur within the first half of the year to 31 March 2018.

The Group is also pleased to report that gross cash balances for the year are £6.9m. This compares to the £6.0m forecast which it highlighted in the earlier statement.

Further detail will be provided within Intercede's final results for the year ending 31 March 2017 which are expected to be published during the week commencing 5 June 2017.

Commenting on the financial close to the year, Richard Parris, Chairman and CEO of Intercede, said;

"After the uncertainty created by the initial phase of the new US Administration, we are pleased that business appears to be returning to normal. Importantly, there is progress in securing the remainder of our near term pipeline and encouraging signs of demand within our core markets. Momentum is building and we view the future with considerable confidence".

Contact

Intercede Group plc

Tel: +44 (0) 1455 558 111

Richard Parris

Chairman & Chief Executive

Andrew Walker

Finance Director

finnCap

Tel: +44 (0) 20 7220 0500

Stuart Andrews

Corporate Finance

Simon Hicks

Corporate Finance

Capital Access Group

Tel: +44 (0) 20 3763 3400

Scott Fulton

Media

Ed Welsby

Investors

About Intercede

Intercede is a software and service company specializing in identity, credential management and secure mobility. Its solutions create a foundation of trust between connected people, devices and apps and combine expertise with innovation to provide world-class cybersecurity. Intercede has been delivering solutions to high profile customers, from the US and UK governments to some of the world's largest corporations, telecommunications providers and information technology firms, for over 20 years. Intercede's product portfolio includes MyID, an identity and credential management system that assigns trusted digital identities to employees citizens and machines. In 2015, Intercede launched MyTAM, enabling trusted applications to be loaded into a mobile device's Trusted Execution Environment (TEE), providing hardware-level security for Android apps. In 2016, Intercede launched RapID, a secure, easy to implement authentication service for mobile apps and cloud services to completely eliminate the need for passwords.

For more information visit: www.intercede.com

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSSSFMLFWSELL
Date   Source Headline
4th Feb 20193:19 pmRNSHolding(s) in Company
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity
18th Jul 20177:00 amRNSDirector/PDMR Shareholding & TVR
13th Jun 20177:00 amRNSCollaborations with VMWare and Imagination
7th Jun 201712:06 pmRNSHolding(s) in Company
7th Jun 201712:01 pmRNSHolding(s) in Company
7th Jun 20177:00 amRNSFinal Results
6th Jun 20177:00 amRNSLaunch of MyIDaaS
25th May 20177:00 amRNSSchedule 2(g) Disclosure
23rd May 20177:00 amRNSAppointment of Chief Sales Officer
17th May 20177:00 amRNSNon-Executive Director Appointment
9th May 20177:00 amRNSContract Win
8th May 20173:45 pmRNSShare Incentive Plan
8th May 20177:00 amRNSIntercede announces Secure Login for WordPress
5th Apr 20177:00 amRNSTrading Update
31st Mar 20177:00 amRNSListing of Convertible Loan Notes
20th Mar 20177:00 amRNSAppointment of VP, US Gov't & Enterprise Sales
15th Mar 20173:03 pmRNSShare Incentive Plan
9th Mar 20177:00 amRNSAppointment of Adviser
3rd Mar 20177:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.